In a phase 4, multicentre, double-blind randomised trial in adults with treatment‑resistant depression, intranasal esketamine monotherapy (56 mg and 84 mg) produced significant reductions in MADRS score versus placebo at day 28 (LS mean differences −5.1 and −6.8; effect sizes 0.48 and 0.63) and demonstrated rapid benefit at 24 hours. The tolerability profile was consistent with prior reports, most commonly nausea, dissociation, dizziness and headache.
- Published
- Journal
- JAMA Psychiatry
- Authors
- Canuso, C. M., Drevets, W. C., Fu, D. J., Janik, A., Lane, R., Macaluso, M., Mattingly, G. W., Popova, V., Qiu, X., Shelton, R. C., Zajecka, J. M.